Genetic variant in a BaP-activated super-enhancer increases prostate cancer risk by promoting AhR-mediated FAM227A expression.

ABSTRACT: Genetic variants in super-enhancers (SEs) are increasingly implicated as a disease risk-driving mechanism. Previous studies have reported an associations between benzo[a]pyrene (BaP) exposure and some malignant tumor risk. Currently, it is unclear whether BaP is involved in the effect of genetic variants in SEs on prostate cancer risk, nor the associated intrinsic molecular mechanisms. In the current study, by using logistic regression analysis, we found that rs5750581T>C in 22q-SE was significantly associated with prostate cancer risk (odds ratio = 1.26, P = 7.61 × 10 ^-5). We also have found that the rs6001092T>G, in a high linkage disequilibrium with rs5750581T>C ( r ² = 0.98), is located in a regulatory aryl hydrocarbon receptor (AhR) motif and may in

SUBMITTER: Fan L 

PROVIDER: S-EPMC11001591 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature